Patrice Nordmann Selected Research

Infections

5/2024	MultiRapid ATB NP test for detecting concomitantly susceptibility and resistance of last resort novel antibiotics available to treat multidrug-resistant Enterobacterales infections.
12/2023	Pharmacokinetic/pharmacodynamic analysis of ceftazidime/avibactam and fosfomycin combinations in an in vitro hollow fiber infection model against multidrug-resistant Escherichia coli.
12/2023	Rapid detection of cefiderocol susceptibility/resistance in Acinetobacter baumannii.
12/2023	Emergence of OXA-48-producing Enterobacter hormaechei in a Swiss companion animal clinic and their genetic relationship to clinical human isolates.
11/2023	Pharmacokinetic/pharmacodynamic evaluation of tigecycline dosing in a hollow fiber infection model against clinical bla-KPC producing Klebsiella Pneumoniae isolates.
10/2023	Rapid Aztreonam/Avibactam NP test for detection of aztreonam/avibactam susceptibility/resistance in Enterobacterales.
10/2023	Rapid meropenem/vaborbactam NP test for detecting susceptibility/resistance in Enterobacterales.
9/2023	Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland.
7/2023	Rapid detection of imipenem/relebactam susceptibility/resistance in Enterobacterales.
1/2023	In vitro-obtained meropenem-vaborbactam resistance mechanisms among clinical Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Patrice Nordmann Research Topics

Disease

50	Infections 05/2024 - 03/2002
8	Urinary Tract Infections (Urinary Tract Infection) 12/2023 - 05/2003
4	Sepsis (Septicemia) 11/2023 - 09/2009
4	Pneumonia (Pneumonitis) 01/2014 - 06/2002
3	Cross Infection (Nosocomial Infection) 11/2022 - 04/2007
2	Community-Acquired Infections 12/2020 - 08/2007
2	Osteomyelitis 01/2019 - 05/2006
2	Enterobacteriaceae Infections 10/2017 - 04/2009
2	Bacteremia 01/2016 - 02/2012
2	Peritonitis 05/2012 - 11/2007
1	Cystic Fibrosis (Mucoviscidosis) 10/2022
1	Healthcare-Associated Pneumonia 04/2022
1	COVID-19 11/2020
1	Critical Illness (Critically Ill) 01/2019
1	Opportunistic Infections (Opportunistic Infection) 01/2015
1	Wounds and Injuries (Trauma) 12/2013
1	Endocarditis 11/2013
1	Chronic Hepatitis B 01/2009
1	Burns 01/2005

Drug/Important Bio-Agent (IBA)

25	Carbapenems (Carbapenem Antibiotics)IBA 10/2023 - 06/2002
13	carbapenemaseIBA 12/2023 - 11/2006
12	Anti-Bacterial Agents (Antibiotics)IBA 05/2024 - 01/2006
7	beta-Lactamases (beta-Lactamase)IBA 01/2019 - 06/2002
6	LactamsIBA 10/2023 - 05/2012
6	Imipenem FDA Link 07/2023 - 03/2002
5	EnzymesIBA 11/2022 - 07/2005
5	Colistin (Coly-Mycin)FDA Link 01/2021 - 03/2012
5	Ceftazidime (Fortum)FDA LinkGeneric 01/2014 - 03/2004
4	Fosfomycin FDA Link 12/2023 - 01/2020
4	Meropenem (Merrem)FDA LinkGeneric 01/2023 - 04/2009
4	AminoglycosidesIBA 10/2022 - 08/2011
3	Cephalosporins (Cephalosporin Antibiotics)IBA 12/2023 - 03/2002
3	CefiderocolIBA 12/2023 - 04/2022
3	Aztreonam FDA LinkGeneric 10/2023 - 01/2014
3	Polymyxins (Polymyxin)IBA 05/2021 - 01/2017
3	Doripenem FDA Link 01/2014 - 05/2011
3	beta-LactamsIBA 04/2009 - 06/2002
2	ceftazidime drug combination avibactamIBA 12/2023 - 01/2023
2	Tigecycline (Tygacil)FDA Link 11/2023 - 03/2012
2	avibactamIBA 10/2023 - 01/2023
2	meropenem and vaborbactamIBA 10/2023 - 01/2023
2	Ertapenem (Invanz)FDA Link 01/2014 - 04/2009
2	Ciprofloxacin (Cipro)FDA LinkGeneric 10/2012 - 04/2006
2	Cefepime (Maxipime)FDA LinkGeneric 11/2007 - 03/2004
2	Clavulanic Acid (Potassium Clavulanate)FDA LinkGeneric 08/2007 - 03/2002
1	Serine (L-Serine)FDA Link 10/2023
1	relebactamIBA 07/2023
1	vaborbactamIBA 01/2023
1	16S Ribosomal RNAIBA 10/2022
1	MethyltransferasesIBA 10/2022
1	oxacillinaseIBA 01/2022
1	Peptides (Polypeptides)IBA 01/2019
1	plazomicinIBA 10/2017
1	Levofloxacin (Levaquin)FDA Link 01/2014
1	Daptomycin FDA Link 11/2013
1	Vancomycin FDA LinkGeneric 11/2013
1	oritavancinIBA 01/2013
1	FluoroquinolonesIBA 10/2012
1	CephalosporinaseIBA 05/2012
1	tRNA MethyltransferasesIBA 08/2011
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2009
1	adefovir dipivoxil (Hepsera)FDA Link 01/2009
1	Hepatitis B e AntigensIBA 01/2009
1	Virulence Factors (Pathogenicity Factors)IBA 03/2008
1	IronIBA 03/2008
1	Tazobactam Drug Combination Piperacillin (Zosyn)FDA LinkGeneric 11/2007
1	2- methyl- 5- trimethylammoniummethyl- 1,3- oxathiolaneIBA 09/2006
1	TL 1IBA 05/2006
1	Norfloxacin FDA Link 04/2006
1	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 03/2004
1	Cefotaxime (Kendrick)FDA LinkGeneric 03/2004
1	Penicillins (Penicillin)FDA Link 05/2003

Therapy/Procedure

2	Therapeutics 09/2023 - 03/2022
1	Salvage Therapy 01/2022
1	Drug Therapy (Chemotherapy) 04/2007